COMMUNIQUÉS West-GlobeNewswire

MEDVi and Male Health: What Current Treatment Options Offer
13/03/2026
New York, NY, March 13, 2026 (GLOBE NEWSWIRE) -- Male health is an important aspect of overall wellness, yet many men overlook early symptoms related to energy levels, hormone balance, and sexual performance. Factors [...]
Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD
13/03/2026
Over 22 million Americans are diagnosed with ADHD — yet an objective biological marker for distinguishing between its three distinct subtypes has, to date, remained elusive 1 Firefly’s AI-powered EEG/ERP technology may [...]
XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation
13/03/2026
Your vote is important – Vote well in advance of the proxy voting deadline: March 20, 2026 XORTX’s board of directors unanimously recommends that Shareholders vote FOR all resolutions Shareholder questions or need [...]
Quantum Cyber (f/k/a Mainz Biomed) Announces Stock Ticker Symbol Change to NASDAQ: QUCY
13/03/2026
BERKELEY, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: QUCY) doing business as Quantum Cyber, today announced, effective upon the commencement of trading on March 12, 2026 (U.S. Eastern Time), [...]
Genenta, Evolving into Saentra Forge, Announces CEO’s Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University
13/03/2026
MILAN, March 13, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge (Nasdaq: SAEN) 1 , a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian [...]
Now Available: Fresh Bloom THCA Flower Subscription Box by The Hemp Doctor
13/03/2026
MOORESVILLE, N.C., March 13, 2026 (GLOBE NEWSWIRE) -- The Hemp Doctor introduces the Fresh Bloom THCA Flower Subscription Box , a monthly drop of hand-selected flower and pre-rolls delivered to your door, including [...]
IBA : Publication des résultats annuels 2025 et conférence web
13/03/2026
La conférence sur les résultats de l’exercice 2025 aura lieu le vendredi 27 mars 2026 à 15h00, heure de Bruxelles Louvain-la-Neuve, Belgique, le 13 mars 2026 - IBA (Ion Beam Applications S.A le leader mondial des [...]
IBA Notice of Full Year 2025 Results and Conference Call
13/03/2026
FY25 results webcast to take place on Friday, 27 March 2026 at 3pm CET Louvain-la-Neuve, Belgium, 13 March 2026 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, [...]
Novonesis issues EUR 1.7 billion senior unsecured notes
13/03/2026
On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed under the newly [...]
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
13/03/2026
VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
13/03/2026
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes [...]
BeautyHealth Reports Full Year and Fourth Quarter 2025 Financial Results
12/03/2026
LONG BEACH, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the full year [...]
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
12/03/2026
Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant Immunotherapy γδ T cells (“DRI [...]
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
12/03/2026
Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026 Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint [...]
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
12/03/2026
Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated soquelitinib [...]
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
12/03/2026
NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation [...]
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
12/03/2026
Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided 1L Consolidation [...]
VitalHub Announces Updated Date for Fourth Quarter and Annual 2025 Results
12/03/2026
TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that it has updated the date for the release of its financial results for the fourth [...]
Picard Medical / SynCardia to Host Annual Business Update Featuring Key Opinion Leaders and Patient Testimonial
12/03/2026
TUCSON, Ariz., March 12, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both [...]

Pages